We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+40.06%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$164M
Cap. Flow
+$47.9M
Cap. Flow %
3.88%
Top 10 Hldgs %
53.52%
Holding
82
New
29
Increased
10
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49M
2
IMCR icon
Immunocore
IMCR
+$34.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.7M
4
SLN
Silence Therapeutics
SLN
+$23.4M
5
ADVM
Adverum Biotechnologies
ADVM
+$22.8M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
ARGX icon
argenx
ARGX
+$55.2M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$35.3M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$29.9M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
CALL
DELISTED
Astria Therapeutics
ATXS
$14.1M 1.14%
+1,000,000
New +$12.5M
CGON icon
27
CG Oncology
CGON
$6.48B
$13.2M 1.07%
+300,000
New +$12.3M
ENGN icon
28
enGene Therapeutics
ENGN
$118M
$12.9M 1.04%
+800,000
New +$9.79M
KYTX icon
29
Kyverna Therapeutics
KYTX
$481M
$12.4M 1.01%
+500,000
New +$14M
VRDN icon
30
Viridian Therapeutics
VRDN
$2.18B
$12.3M 0.99%
700,000
+100,000
+17% +$1.94M
CGEM icon
31
Cullinan Oncology
CGEM
$1.07B
$11.9M 0.97%
+700,000
New +$10.8M
IMTX icon
32
Immatics
IMTX
$1.18B
$10.5M 0.85%
+1,000,000
New +$11.7M
SYRE icon
33
Spyre Therapeutics
SYRE
$8.69B
$9.48M 0.77%
250,000
+100,000
+67% +$2.9M
FULC icon
34
CALL
Fulcrum Therapeutics
FULC
$249M
$9.44M 0.76%
+1,000,000
New +$8.93M
LCTX icon
35
Lineage Cell Therapeutics
LCTX
$257M
$9.25M 0.75%
+6,250,000
New +$7.09M
PRAX icon
36
Praxis Precision Medicines
PRAX
$8.8B
$9.15M 0.74%
+150,000
New +$6.73M
APLT
37
DELISTED
Applied Therapeutics
APLT
$8.98M 0.73%
1,350,000
-310,000
-19% -$1.39M
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.82B
$8.33M 0.67%
+350,000
New +$7.81M
TRVI icon
39
Trevi Therapeutics
TRVI
$2.57B
$7.59M 0.61%
+2,200,000
New +$4.91M
ANNX icon
40
CALL
Annexon
ANNX
$841M
$7.17M 0.58%
+1,000,000
New +$5.19M
CYTK icon
41
Cytokinetics
CYTK
$10.9B
$7.01M 0.57%
100,000
-1,525,000
-94% -$118M
KURA icon
42
Kura Oncology
KURA
$901M
$6.4M 0.52%
+300,000
New +$5.83M
NMRA icon
43
Neumora Therapeutics
NMRA
$308M
$6.19M 0.5%
382,345
– –
ATYR
44
aTyr Pharma
ATYR
$48M
$6.04M 0.49%
3,100,000
-2,750,000
-47% -$4.8M
JANX icon
45
Janux Therapeutics
JANX
$950M
$5.65M 0.46%
+150,000
New +$3.27M
LRMR icon
46
CALL
Larimar Therapeutics
LRMR
$398M
$5.31M 0.43%
+700,000
New +$5.45M
ELEV
47
DELISTED
Elevation Oncology
ELEV
$5.13M 0.42%
+1,000,000
New +$3.24M
NXTC icon
48
NextCure
NXTC
$20.8M
$4.29M 0.35%
+160,417
New +$2.76M
ALLK
49
DELISTED
Allakos
ALLK
$3.65M 0.3%
2,900,000
– –
UNCY icon
50
Unicycive Therapeutics
UNCY
$141M
$3.01M 0.24%
+346,993
New +$4.21M
1
2
3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2024 Portfolio in Review

As of Q1 2024, Logos Global Management held 82 positions worth $1.24B, up 15% from $1.07B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $47.9M of net new capital in Q1 2024, opening 29 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 400,000 shares worth $51.8M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $118M trimmed.

  • Logos Global Management's largest Q1 2024 buy was Sarepta Therapeutics: 400,000 shares worth $51.8M.
  • Logos Global Management added most to Immunocore in Q1 2024, an estimated $34.3M increase.
  • Logos Global Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $118M.
  • Logos Global Management fully exited argenx in Q1 2024, selling an estimated $55.2M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q1 2024.
  • Logos Global Management opened 29 new positions and closed 25 in Q1 2024.
  • Logos Global Management's portfolio value rose 15% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.